论文部分内容阅读
目的探讨利卡汀和利卡汀联合碘油及化疗药物治疗原发性肝癌(PHC)的近期临床疗效。方法已确诊的PHC患者72例,采用肝动脉灌注介入术(TACE),其中单纯利卡汀介入治疗50例,利卡汀+碘油+吡柔比星+丝裂霉素介入治疗22例,检测治疗前和治疗后1个月AFP值、肿瘤大小、肝肾功能、外周血白细胞、红细胞、血小板的变化。结果单纯利卡汀组治疗1个月后,肿瘤瘤体明显缩小、AFP有所下降但无统计学意义;外周血白细胞、红细胞、血小板、肝肾功无明显变化。利卡汀+碘油+化疗药治疗1个月后肿瘤瘤体和AFP明显下降,外周血白细胞、红细胞、血小板、肝肾功无明显变化。结论两组介入治疗PHC,均能使瘤体缩小、AFP下降,以利卡汀+碘油+化疗药效果更好,治疗前后外周血白细胞、红细胞、血小板、肝肾功无明显变化,表明利卡汀和(或)利卡汀联合碘油及化疗药介入治疗中晚期原发性肝癌近期疗效显著、安全。
Objective To investigate the short-term clinical efficacy of liketatin and likacin in combination with lipiodol and chemotherapy drugs in the treatment of primary hepatocellular carcinoma (PHC). Methods Twenty-two PHC patients were enrolled in this study. Hepatic arterial perfusion (TACE) was used in this study. Among them, 50 cases were treated with limatin alone, 22 cases were treated with likinatin, lipiodol and pirarubicin plus mitomycin, AFP values, tumor size, liver and kidney function, peripheral white blood cells, erythrocytes and platelets were measured before treatment and one month after treatment. Results After 1 month of treatment with likatin alone, tumor size was significantly reduced and AFP was decreased but not statistically significant. Peripheral blood leucocytes, erythrocytes, platelets, liver and kidney function had no significant changes. After 1 month of treatment with likatin + lipiodol + chemotherapeutic drugs, the tumors and AFP decreased significantly. No significant changes were found in peripheral blood leucocytes, erythrocytes, platelets, liver and kidney function. Conclusion Both groups can reduce the size of the tumor and decrease the AFP in the interventional treatment of PHC. There is no significant change in peripheral blood leucocytes, erythrocytes, platelets, liver and kidney before and after treatment with likatin + lipiodol + chemotherapeutic drugs. Cardin and (or) Licatin combined lipiodol and chemotherapy drugs in the treatment of advanced primary liver cancer in the short term effect is significant and safe.